Support teaching, research, and patient care.
Solid Tumors, Bone Sarcomas, Global Oncology, Health Disparities
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or
refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain
tumors for which there are no standard treatment options with curative potential.
View full details
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and
ipilimumab, and to see how well they work in treating patients with cancers that have come
back (relapsed) or does not respond to treatment (refractory) and have an increased number of
genetic changes. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Tumor mutational burden (TMB) is the total amount of genetic
changes or "mutations" found in tumor cells. Some studies in adults with cancer have shown
that patients with a higher TMB (an increased number of genetic changes) are more likely to
respond to immunotherapy drugs. There is also evidence that nivolumab and ipilimumab can
shrink or stabilize cancer in adult patients with cancer. This study is being done to help
doctors learn if the combination of nivolumab and ipilimumab can help children, adolescents,
and young adults patients live longer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.